Revenue segments as reported by the company.

Smokeable Products

Oral Tobacco Products

Wine

All Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, administration and research costs

Asset impairment and exit costs

Amortization of intangibles

General corporate expenses

Corporate asset impairment and exit costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Altria

Altria Group, Inc. operates as a holding company, which engages in the manufacture and sale of cigarettes in the United States. It operates through the following segments: Smokeable Products, Oral tobacco products, and Wine. The Smokeable Products segment consists of cigarettes manufactured and sold by PM USA and machine-made large cigars and pipe tobacco manufactured and sold by Middleton. The Oral tobacco products segment is primarily moist smokeless tobacco products (MSTs) through brands like Copenhagen and Skoal as well as on! oral nicotine pouches sold by Helix. The Wine segment, through subsidiary Ste. Michelle Wine Estates Ltd, produces Washington State wines, primarily Chateau Ste. Michelle and 14 Hands, and owns wineries in or distributes wines from several other wine regions. The company was founded in 1919 and is headquartered in Richmond, VA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Altria reports robust Q4 earnings, focuses on innovation and growth

Altria's Q4 2022 performance reflects resilience amidst industry challenges, with a focus on innovation and shareholder returns. The company's strategic initiatives in smoke-free products and digital engagement underscore its commitment to long-term growth and harm reduction.

Altria reports resilient Q1 performance amid industry challenges and opportunities

Altria's Q1 2023 earnings call highlighted strong performance amidst industry challenges, emphasizing harm reduction and regulatory compliance. The company faces hurdles from inflation, regulatory changes, and evolving consumer behaviors, while focusing on growth opportunities in smoke-free products and strategic investments.

Altria reports solid Q2 earnings, eyes e-vapor growth opportunities

Altria's focus on smoke-free products and NJOY acquisition driving growth.
Challenges in the cigarette industry due to economic pressures and flavor bans.
Opportunities in the e-vapor category and expansion plans in the U.S.
Strong balance sheet and significant capital returns to shareholders.

Altria reports growth in earnings, navigates regulatory challenges in e-vapor

Altria's Q3 2023 earnings call highlighted solid financial performance, strategic focus on e-vapor products, and efforts to combat illegal vape products. The company faces challenges from regulatory uncertainties and illicit products but sees opportunities in expanding NJOY's reach and addressing market gaps.

Altria reports growth in smoke-free products amidst regulatory challenges

Altria's Q4 2023 earnings call highlighted growth in adjusted EPS, strategic focus on smoke-free products, and efforts to combat illicit e-vapor products. The company faces challenges in competitive segments and economic pressures but sees opportunities in new product introductions and regulatory collaborations.

Altria reports mixed Q1 performance, focuses on growth strategies

Altria's Q1 performance showed growth in NJOY and oral tobacco segments, with challenges in EPS decline and economic pressures on consumers.
Strengths include reaffirmed EPS guidance, strategic investments, and focus on combating illicit e-vapor products.
Opportunities lie in maximizing profitability in oral tobacco, product positioning, and capturing transitioning consumers.
Overall, Altria's performance reflects a mix of growth, challenges, and strategic opportunities in navigating market dynamics.

Altria's NJOY drives growth as company navigates e-vapor challenges

Altria's Q2 2024 earnings call showcased strong performance in smoke-free products, highlighting growth in retail share and volume momentum. Despite challenges in the e-vapor category, the company remains focused on responsible regulation and enforcement. With a commitment to shareholder value and long-term growth strategies, Altria is poised for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Altria Group, Inc. is a holding company, which engages in the manufacture and sale of cigarettes in the United States. It operates through the following segments: Smokeable Products, Oral Tobacco Products, and All Other. The Smokeable Products segment consists of cigarettes manufactured and sold by PM USA, and machine-made large cigars and pipe tobacco manufactured and sold by Middleton. The Oral Tobacco Products segment includes MST and snus products manufactured and sold by USSTC, and oral nicotine pouches manufactured and sold by Helix. The All Other segment refers to the financial results of NJOY, Helix ROW, and the IQOS System heated tobacco business. The company was founded in 1919 and is headquartered in Richmond, VA.

Altria shares have shed nearly 50% of their value, based largely on fears of a regulatory crackdown across the vaping industry.

Why Altria Will Beat The S&P 500 From Here

While I believe that regulators will ultimately get this entire health scare sorted and both Juul and Cronos will go back to running their businesses, I can’t help but think how relieved Altria’s management must be that they made the $1.8 billion investment in Cronos in exchange for 45% of its stock. 
The post Altria’s Juul Labs Investment Not Looking So Hot  appeared first on InvestorPlace.

Altria’s Juul Labs Investment Not Looking So Hot 

British American Tobacco

They're already the fastest-growing tobacco product, and e-cig troubles could catapult them higher.

With E-Cigs Under Pressure, Are Nicotine Pouches a Better Alternative?

On it's surface, Altria stock looks cheap. But less demand for tobacco products and vaping crisis headlines mean its fairly valued for now.

Steer Clear of Altria Stock Amid the E-Cigarette Crisis

The chance that Altria writes down the value of its $12.8 billion investment in Juul has "increased materially" amid uncertainty around the e-cigarette industry, Fitch credit analysts say.

Altria's chance of writing down its Juul investment has 'increased materially,' Fitch says

Philip Morris

It's generic packaging that can be bought cheaply and have a homebrew e-liquid added.

Illicit THC Vape Brand May Be Responsible for E-Cig Illnesses, Deaths

ARMOUR Residential REIT

New American High Income Fund

New Mountain Finance

Let’s explore some high-dividend picks doling out fat yields ranging from 7.5% to 12.2%.

How To Build The Perfect Retirement Income Portfolio

Beyond Meat

Johnson & Johnson

Mylan

iShares MSCI USA ESG Select ETF

Investors need to look beyond Balance Sheets and Income Statements.

These Companies Will Boost Your Portfolio Performance... And Your Morale

Iqos isn't a vaping device nor is it a cigarette. It heats tobacco, but doesn't burn it, giving users the same rush of nicotine as smoking without as much damage to their lungs.

Altria launches Iqos tobacco device in US, and the timing couldn't be better

Imperial Brands PLC

Limit orders are one of three ways I buy stocks for my retirement portfolio.

6 Buy Orders I Have Open For My Retirement Portfolio

Aurora Cannabis

Cronos Group

With vaping-related illnesses on the rise, health concerns could impact the success of a new wave of cannabis products set to launch in Canada later this year.

Vape Sales are Falling: Why this Could Be Bad News for Canadian Cannabis Companies

Altria's weakness can largely be attributed to the previous decade's outperformance, a slight acceleration in smoking rate decline, and the ongoing government crackdown on e-cigarettes.

Altria Is Extremely Cheap: A Look At The Underlying Issues And Math

AbbVie

Allergan

Brookfield Property REIT Inc. - Ordinary Shares - Class A

Brookfield Property Partners

My retirement portfolio goal is maximum safe long-term income, investing in quality companies bought at good to great prices, run by competent or excellent management teams I can trust.

Why I Have 28% Of My Retirement Portfolio Invested In These 3 High-Yield Blue Chips

The leading e-cig maker is under attack as illness, death, and faith in its ability to meet challenges grow.

Altria's $13 Billion Juul Investment Is Going Up in Smoke

Carnival

Centene

FedEx

Twenty-First Century Fox

UnitedHealth Group

According to GuruFocus’ list of 52-week lows, these guru stocks have reached their 52-week lows.

52-Week Company Lows (Sep 30)

Enterprise Products Partners

The 24-hour news cycle means we're constantly inundated with scary headlines creating fear of an imminent market downturn.

The Best Dividend Stocks To Buy In October

Bristol-Myers

Nordstrom

Despite substantial share price declines, these brand-name dividend stocks aren't yield traps.

3 Beaten-Down Dividend Stocks You Can Trust

Altria has been a tremendous performer for a very long time.

Why Altria Is A Bad Investment For The Long Term

Altria is joining my list of scandal-affected stocks due to the vaping investigations targeting Juul Labs.

Altria Primed To Follow Pattern For Scandal Stocks

Gilead Sciences

Regeneron Pharmaceuticals

Gilead Sciences, Altria, Regeneron Pharmaceuticals and Carnival present buying opportunities

Stocks That Fell to 3-Year Lows in the Week of Sept. 27

A once-promising union to take on global competition has been definitively stubbed out.

Philip Morris Ends Merger Talks With Altria as Juul Woes Mount

Philip Morris (PM) rose 5 percent on Wednesday, after it announced that merger talks with Altria (MO) had ended. However, our view is that the stock will fail, as the current market cycle matures.

Philip Morris Ends Merge Talks With Altria, Faces Murky Future

Altria (MO) scraps plans to merge with Philip Morris and announces leadership change for JUUL.

News for Altria Stock (MO)